Literature DB >> 1905737

Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.

R Abs1, P M Parizel, A Beckers.   

Abstract

A 68-year-old male patient presented with visual impairment due to a large pituitary tumor. After transsphenoidal adenomectomy the elevated serum FSH levels were lowered but not normalized. Deterioration of the vision was detected five years later and tumor regrowth was evidenced. The patient was treated with the long-acting and repeatable form of bromocriptine (Parlodel-LAR). Three days after the first intramuscular injection it already resulted in an important improvement of the visual field defects. Serum FSH concentration was suppressed during a prolonged period, but no change in the size of the pituitary adenoma was recorded on CT scan. Long-term oral treatment with bromocriptine resulted in a sustained suppression of the serum FSH levels, without further visual improvement, but with a significant reduction of the volume of the adenoma. The rapid and prolonged effect of Parlodel-LAR upon the FSH secretion, with a possible correction of the visual field defects and a reduction of the tumor mass, could make this medication appropriate as adjunctive treatment in some gonadotroph cell adenomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905737     DOI: 10.1007/BF03350285

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  10 in total

Review 1.  Medical therapy of glycoprotein hormone-secreting pituitary tumors.

Authors:  D S Oppenheim; A Klibanski
Journal:  Endocrinol Metab Clin North Am       Date:  1989-06       Impact factor: 4.741

2.  Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine.

Authors:  M Berezin; D Olchovsky; A Pines; R Tadmor; B Lunenfeld
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

3.  Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine.

Authors:  M L Vance; E C Ridgway; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1985-09       Impact factor: 5.958

Review 4.  Gonadotroph cell adenomas of the pituitary.

Authors:  P J Snyder
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

5.  Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone.

Authors:  E del Pozo; K Schlüter; E Nüesch; J Rosenthaler; L Kerp
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201-995).

Authors:  G Sassolas; P Serusclat; B Claustrat; J Trouillas; S Merabet; R Cohen; J C Souquet
Journal:  Horm Res       Date:  1988

7.  Response of luteinizing hormone secreting pituitary adenoma to a long-acting somatostatin analogue.

Authors:  P Vos; R J Croughs; J H Thijssen; J W van 't Verlaat; L A van Ginkel
Journal:  Acta Endocrinol (Copenh)       Date:  1988-08

8.  Follicle-stimulating hormone-secreting pituitary adenomas.

Authors:  A Beckers; A Stevenaert; K Mashiter; G Hennen
Journal:  J Clin Endocrinol Metab       Date:  1985-09       Impact factor: 5.958

9.  Follicle-stimulating hormone-secreting pituitary adenomas: correlation of reduction of adenoma size with reduction of hormonal hypersecretion after transsphenoidal surgery.

Authors:  R I Harris; N J Schatz; T Gennarelli; P J Savino; W H Cobbs; P J Snyder
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

10.  Discordant serum alpha-subunit and FSH concentrations in a woman with a pituitary tumour.

Authors:  A J Chapman; I A MacFarlane; S M Shalet; C G Beardwell; J Dutton; M L Sutton
Journal:  Clin Endocrinol (Oxf)       Date:  1984-08       Impact factor: 3.478

  10 in total
  3 in total

1.  Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.

Authors:  G Leese; R Jeffreys; J Vora
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

2.  Flutamide and hirsutism.

Authors:  T Motta; G Maggi; A D'Alberton
Journal:  J Endocrinol Invest       Date:  1994-09       Impact factor: 4.256

Review 3.  Updating the Landscape for Functioning Gonadotroph Tumors.

Authors:  Georgia Ntali; Cristina Capatina
Journal:  Medicina (Kaunas)       Date:  2022-08-08       Impact factor: 2.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.